Urinary cysteinyl leukotriene E 4  significantly increases during pain in children and adults with sickle cell disease | Zendy

Field Joshua J. | Zendy; Strunk Robert C. | Zendy; KnightPerry Jessica E. | Zendy; Blinder Morey A. | Zendy; Townsend R. Reid | Zendy; DeBaun Michael R. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Urinary cysteinyl leukotriene E 4 significantly increases during pain in children and adults with sickle cell disease

Author(s) -

Field Joshua J.,

Strunk Robert C.,

KnightPerry Jessica E.,

Blinder Morey A.,

Townsend R. Reid,

DeBaun Michael R.

Publication year - 2009

Publication title -

american journal of hematology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.456

H-Index - 105

eISSN - 1096-8652

pISSN - 0361-8609

DOI - 10.1002/ajh.21370

Subject(s) - leukotriene e4 , medicine , creatinine , leukotriene receptor , cohort , leukotriene , pathogenesis , gastroenterology , leukotriene d4 , disease , urinary system , immunology , asthma

Baseline level of the cysteinyl leukotriene (CysLT), leukotriene E 4 (LTE 4 ), is associated with an increased pain rate in children and adults with sickle cell disease (SCD). To provide additional evidence for a role of CysLTs in the pathogenesis of vaso‐occlusion, we tested the hypothesis that LTE 4 levels will increase within an individual during painful episodes compared to baseline. In a cohort of 19 children and adults with SCD, median LTE 4 levels increased from 82.36 pg/mg creatinine at baseline to 162.81 pg/mg creatinine during a painful episode ( P < 0.001). These data further support a contribution of CysLTs to the process of vaso‐occlusion. Am. J. Hematol., 2009. © 2009 Wiley‐Liss, Inc.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research